1. Hahn EF, Busso ME, Miami AM, and Resnick L. Nucleotide dimers as anti-HIV agents, in Martin JC, (ed): Nucleotide analogs as antiviral agents. ACS Symposium series, Washington DC, 1989; 401: 156-169.

  2. Resnick L., Busso ME, and Duncan RC, Anti-HIV screening technology. Heterosexual transmission of AIDS. Alexander N (ed). Wiley-Liss 1989; 311-327.

  3. Busso M. Cosmetic Dermatology Procedure Manual. Leonard AL and Hanke CW (ed). Physicians’ Continuing Education Corp. 2007; 67-72.

  1. Busso ME, Mian AM, Hahn EF, and Resnick I. Nucleotide dimers suppress HIV expression in vitro. AIDS Res Hum Retroviruses. 1988; 4:449-455.

  2. Agarwal RP, Busso ME, Mian AM, and Resnick L. Uptake of 2', 3' dideoxyadenosine in HIV infected and non-infected human cells. AIDS Res Hum Retroviruses. 1989; 5:527-536.

  3. Davila E, Wallack MK, Resnick L, Busso ME, Gronka S, Darnell E. and Bash JA. Clinical response to IL-2/LAK therapy of advanced melanoma in an HIV positive patient. Cancer Detection and Prevention. 1989; 7:835-839.

  4. Busso ME,Resnick L, Yang BH, and Mian AM. Cellular pharmacology and anti-HIV activity of 2' ,3' dideoxyguanosine.AIDS Res Hum Retroviruses; 6:1991-1995.

  5. Busso ME and Resnick L. Anti-HIV effects of dextran sulfate are strain dependent and antagonistic or synergistic when dextran sulfate is given in combination with dideoxynucleosides. Antimicrob Agents Chemother 1990; 34: 19911995.

  6. Busso ME, Thornwaite J, and Resnick L. HIV-induced syncytium formation requires the formation of conjugates between virus infected and uninfected T-cells in vitro. AIDS 1991; 5:1425 1432.

  7. Romero DL, Busso ME, Tan CK, Reusser F, Palmer JR, Poppe SM, Aristoff PA, Downey KM, So AG, Resnick L. and Tarpley WG. Novel bisheteroarylpiperazine HIV-1 reverse transcriptase inhibitors which potently inhibit viral replication in vitro. Proc Natl Acad Sci USA 1991; 88:8806-8810.

  8. Althaus IW, LeMay RJ, Gonzalez AJ, Deibel MR, Sharma SK, Kezdy FJ, Resnick L, Busso ME, Aristoff PA, and Reusser F. Enzymatic kinetics studies with the non nucleoside HIV RT inhibitor U-9843. Experience 1992; 48: 1127-1132.

  9. Romero DL, Morge RA, Genin MJ, Biles C, Busso ME, Resnick L, Althaus IW, Reassure F, Thomas RC, and Tarpley WG. BHAP reverse transcriptase inhibitors: Structure activity relationships of novel subs-tituted indole analogues and the indentification of a second generation chemical candidates. (J. Med Chem. 1993;36:1505-1508.

  10. Dueweke TJ, Poppe SM, Romero DL, Swaney SM, So AG, Downey Km, Althaus IW, Reusser F, Busso ME, Resnick L, Mayers DL, Lane, Aristoff, Thomas RC, and Tarpley WG. U-90152; a potent inhibitor of HIV-1 replication. Antimicrob. Agents Chemother. 1993; 37:1127-1131.

  11. Romero DL, Morge RA, Biles C, Berrios-Pena N. May P, Palmer JR, Johnson PD, Smith HW, Busso ME,Tan CK, Voorman R, Reusser F, Althaus IW, Downey KM, So AG, Resnick L, Tarpley WG, and Aristoff P. Discovery, Synthesis and Bioactivity of Bis (heteroaryl) piperazines (BHAPs): A Novel Class of Non-nucleoide HIV-1 ReverseTranscriptase Inhibitors. J Med Chem 1994, 37: 999-1014.

  12. Busso ME and Resnick L. Development of an assay that detects transcriptionally component Human Immunodeficiency Virus type one particles. J of Virol Methods 1994, 47: 129-140.

  13. Busso ME and Berman B. Antivirals in Dermatology. J Am Acad Dermatol 1995,32: 1031-1040. Althaus IW, Chou KC, Kezdy FJ, Resnick L, Busso ME, So Ag, Downey KM, Romero DL, Thomas RC, Aristoff PA, Tarpley WG, Reusser F. The benzylthio­ pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase. Biochem Pharmacol 1996 Mar 22;51(6): 743-750.

  14. Nouri K, Busso ME, Machler BC. Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C. Cutis. 1997;60:289-290.

  15. Elgart GW, Hanly A, Busso ME,Spencer JM. Bednar tumor (pigmented dermatofibrosarcoma protuberans) occurring in a site of prior immunization: immunochemical findings and therapy. J Am Acad Dermatol 1999 Feb; 40(2 Pt 2):315- 317.

  16. Lemperle G, Romano JJ and Busso ME.Soft tissue augmentation with artecoll: IO­ year history, indications, techniques, and complications. Dermatol Surg. 2003 Jun;29(6):573-87; discussion 587.

  17. Cohen SR, Bemer CF, Busso M, Gleason MC, Hamilton D, Holmes RE, Romano JJ, Rullan PP, Thaler MP, Ubogy Z, Vecchione TR. ArteFill: a long-lasting injectable wrinkle filler material— Summary of the U.S. Food and Drug Administration trials and a progress report on 4- to 5-year outcomes. Plast Reconstr Surg. 2006 Sep;118(3 Suppl):64S-76S

  18. Busso M and Karlsberg P. Cheek augmentation and rejuvenation using injectable calcium hydroxylapatite (Radiesse).Cosmet Dermatol 2006.Sep;19(9):583-588.

  19. Busso M and Applebaum D. Hand augmentation with Radiesse. Dermatologic Therapy 2007. Dec; 20:385-387.

  20. Graivier M,. Bass LS, Busso M, Jasin M, Narins R,Tzikas T. “Calcium Hydroxy/apatite (RADIESSE) for Correction of the Mid- and Lower Face: Consensus Recommendations”Journal of Plastic and Reconstructive Surgery -up:

  21. Smith S, Busso M, McClaren M, Bass LS. A randomized. bilateral, prospective comparison of calcium hydroxylapa tite microspheres \./ versus human-based collagen for the correction of nasolabial folds.Dermatol Surg. 2007 Dec;33 Suppl 2:S112-21; discussion S121

  22. Cohen SR; Berner CF, Busso M, Clopton P, Hamilton D, Romano JJ, Rull-an PP , Thaler MP,Ubogy Z, Vecchione TR. Five-year safety and’ efficacy·of a novel polymethylmethacrylate aesthetic soft tissue filler for the correction of nasolabial folds. Dermatol Surg. 2007 Dec;33 Suppl 2:S222-30

  23. Graivier MH , Bass LS, Busso M, Jasin ME, Narins RS, Tzikas TL. Calcium h drox la atite Radiesse for correction of the mid- and lower face: consensus recommendations Plast Reconstr Surg. 2007 Nov;120(6 Suppl):55S-66S.

  24. Busso M, Voigts R. An investigation of changes in physical properties of injectable calcium hydroxylapatite in a carrier gel when mixed with lidocaine and with lidocaine/epinephrine Dermatol Surg. 2008 Jun;34 Suppl 1:S16-23; discussion S24.

  25. Busso M. Soft tissue augmentation: nonsurgical approaches to treatment of the mid and lower facial regions. Dermatol Nurs. 2008 Jun;20(3):211-4, 217-9

  26. Marmur E, Green L, Busso M. Controlled, randomized study of pain levels in subjec ts treated with calcium hydroxvlapatite, premixed with lidocaine for correction of nasolabial folds. Dermato l Surg. 2010 Mar;36(3):309-15. doi: 10.1111/j.1524-4725.2009.01435

  27. Busso M,Moers-Carpi M, Storck,R, Ogilvie P, Ogilvie A. Multicenter, Random ized Trial Ass essin g The Effectiveness And Safety Of Calcium Hydroxylapatite for hand rejuvenation. Dermatologic Surgery. Volume 36, Issue 1, 2010, Pages: 790-797

  28. Bass LS, Smith S, Busso M, McClaren M. Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results. Aesthet Surg J. 2010 Mar;30(2):235-88.

  29. Busso M Additional commentary on “addition of lidocaine to fillers”. Dermatol Surg. 2010 Nov;36(11): 1795-6.

  30. Busso M, Howell DJ. Forehead recontourinq using calcium hydroxylapatite. Dermatol Surg. 2010 Nov;36 Suppl 3:1910-3.

  31. Redbord KP, Busso M, Hanke CW. Soft-tissue augmentation with hyaluronic acid and calcium hydroxyl apatite fillers. Dermatol Ther. 2011 Jan-Feb;24(1):71-81. Doi:10.1111/j. 1529-8019.2010

  32. Hanke CW, Rohrich RJ, Busso M, Carruthers A, Carruthers J, Fagien S, Fitzgerald R, Glogau R,et al. Facial Soft-Tissue Fillers: Assessing the State of the Science conference-Proceedings report. J Am Acad Dermatol. 2011 Apr;64(4 Suppl):S53-65.

  33. Hanke CW, Rohrich RJ, Busso M, Carruthers A, Carruthers J, Fagien S, Fitzgerald R, Glogau R, et al. Facial Soft-Tissue Fillers conference: Assessing the State of the Science. J Am Acad Dermatol. 2011 Apr;64(4 Suppl):S66-85, S85.e1-136. doi: 10.1016/j.jaad.2011.02.009.

  34. Rohrich RJ, Hanke CW, Busso M, Carruthers A, Carruthers J, Fagien S, Fitzgerald R, Glogau R, et al. Facial soft-tissue fillers conference: assessing the state of the science. Plast Reconstr Surg. 2011 Apr;127(4 Suppl):22S-S. Erratum in: Piast Reconstr Surg. 2011 May;127(5):2138-9

  35. Hanke CW, Moy RL, Roenigk RK, Roenigk HH Jr, Spencer JM, Tierney EP, Bartus CL, Bernstein RM, Brown MD, Busso M,Carruthers A, Carruthers J, lbrahimi OA, Kauvar AN, Kent KM, Krueger N, Landau M, Leonard AL, Mandy SH, Rohrer TE, Sadick NS, Wiest LG. Current status of surgery in dermatology. J Am Acad Dermatol. 2013 Dec;69(6):972-1001.

  36. Busso M,Applebaum D, Tzickas T et al. Hyaluronic acid fillers: the science. Prime 2014;2(2):42-48

  37. Lefebvre-Vilardebo M, Trevidic P, Moradi A, Busso M, Sutton AB, Bucay VW. Hand: Clinical Anatomy and Regional Approaches with Injectable Fillers. Plast Reconstr Surg. 2015 Nov;136(5 Suppl):258S-275S.

  38. Jacob, B. Kinney, Busso, et al High Intensity Focused Electro-Magnetic Technology (HIFEM) for Non-Invasive Buttocks A Lifting and Toning of Gluteal Muscles: A Multi-Center Efficacy and Safety Study. Journal of Drugs in Dermatology. 2018 Nov (17) in print.

  39. Busso M, Denkova R (2019) High-Intensity Focused Electromagnetic (HIFEM) Field Therapy Used for Non-Invasive Buttock Augmentation and Lifting: Feasibility Study. J Aesthet Reconstr Surg. Vol 5 No.1:2.

  40. Busso M. A new approach to Thread Facelifting. J Drugs Dermatol. 2021 Oct 1;20(10):1085-1090.

  41. Duncan DI, Busso M.Effectiveness of combined use of targeted pressure energy, radiofrequency, and high-intensity focused electromagnetic fields to improve skin quality and appearance of fat and muscle tissue in different body parts. J Cosmet Dermatol. 2023 Jan;22(1):200-205.

  42. Busso M., Born T. Combined Monopolar Radiofrequency and Targeted Pressure Energy for the Treatment and Improvement of Cellulite Appearance on Multiple Body Parts J Clin Aesthet Dermatol. 2023 May;16(5):35-39.

  43. Busso M. Performing Advanced Thread Lifts. Aesthetics. 2023 July;10(8):49-51.